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Objective: The 5-year survival for patients with surgically resected stage I non–small
cell lung cancer is only 60% to 70%, probably because of undetected systemic occult
micrometastases. Detection of occult micrometastases in lymph nodes by
reverse–transcriptase polymerase chain reaction for carcinoembryonic antigen mes-
senger RNA in non–small cell lung cancer has not been reported. Detection of occult
micrometastases by standard reverse–transcriptase polymerase chain reaction pro-
vides only yes or no answers about their presence, whereas quantitative real-time
reverse–transcriptase polymerase chain reaction permits reproducible quantitation of
target molecules. This study evaluated the ability of quantitative reverse–transcrip-
tase polymerase chain reaction to quantitate lymph node occult metastases with car-
cinoembryonic antigen messenger RNA as a tumor marker.
Methods: Standard reverse–transcriptase polymerase chain reaction and quantita-
tive reverse–transcriptase polymerase chain reaction for carcinoembryonic antigen
messenger RNA were performed on 232 lymph nodes from 53 patients with stage I
disease (node negative according to histologic examination). Quantitative
reverse–transcriptase polymerase chain reaction determined carcinoembryonic anti-
gen messenger RNA quantity by detecting fluorescence increase at a threshold
polymerase chain reaction cycle. Threshold polymerase chain reaction cycle values
were correlated with standard curves created from serially diluted carcinoembry-
onic antigen–positive HTB-174 tumor cells to estimate the number of micro-
metastatic tumor cells in a lymph node.
Results: Detection rates of occult metastases were similar for standard reverse–tran-
scriptase polymerase chain reaction and quantitative reverse–transcriptase poly-
merase chain reaction at 38 of 232 (16.4 %) and 59 of 232 (25.4 %), respectively.
Upstaging rates among 53 cases of stage I non–small cell lung cancer were also
similar for standard reverse–transcriptase polymerase chain reaction and quantita-
tive reverse–transcriptase polymerase chain reaction at 23 of 53 (43.4 %) and 30 of
53 (56.6%), respectively. Comparison of positive lymph node stations according to
quantitative reverse–transcriptase polymerase chain reaction (threshold polymerase
chain reaction cycle <45) with HTB-174 tumor cell standard curves yielded esti-
mates of metastatic tumor cell burden of 1.07 × 103 to 3.24 × 105 cells per lymph
node station (median 7190 tumor cells per lymph node station).
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Lung cancer is the most common cause ofdeath by malignancy in the United States.1Survival after surgical resection ofnon–small cell lung cancer (NSCLC) isdetermined by postoperative pathologicstage, but only 60% to 70% of patients with
stage I disease (node negative) survive 5 years,2 underscor-
ing the high rate of occult micrometastases in “early stage”
lung cancer.
Detection of systemic occult micrometastases is possible
with immunohistochemical analysis and reverse transcrip-
tase–polymerase chain reaction (RT-PCR). The presence of
occult micrometastases in lymph nodes and bone marrow of
patients with surgically resected NSCLC, as detected by
immunohistochemical analysis (with either cytokeratin
antibodies or Ber-EP4 antibodies), correlates with a higher
risk of tumor recurrence and death.3,4 The prognostic value
of occult micrometastatic detection by RT-PCR for tumor-
specific messenger RNA (mRNA) in NSCLC is unknown.
We previously reported on RT-PCR detection of apomucin
type 1 (MUC-1) mRNA in lymph nodes as a means of
detecting occult micrometastases5; however, subsequent
studies revealed the ubiquitous presence of MUC-1 mRNA
in many tissues, diminishing its value as a tumor marker.6-8
Carcinoembryonic antigen (CEA) is a 200-kd cell-
surface glycoprotein involved in cell-to-cell adhesion. RT-
PCR detection of CEA mRNA has been used as a marker of
occult micrometastases in blood, bone marrow, and lymph
nodes of patients with gastrointestinal and breast malignan-
cies.9,10 Detection of occult micrometastases with RT-PCR
for CEA mRNA has been reported in the peripheral blood
of patients with NSCLC.11,12 However, detection of occult
micrometastases in lymph nodes has not been reported.
A potential shortcoming of occult micrometastatic detec-
tion by immunohistochemical analysis and standard RT-
PCR is the binary yes or no result regarding occult
micrometastases’ presence or absence. Although they are
predictive of increased tumor recurrence risk, simple yes or
no results fail to further stratify risk. Studies of N2 disease
detected by hematoxylin and eosin staining revealed signif-
icant survival differences between patients with lymph
nodes replaced by tumor and patients with microscopic dis-
ease found incidentally after surgical resection.13 In a simi-
lar vein, tumor recurrence and survivals among patients
with lymph nodes negative according to hematoxylin and
eosin staining that harbor occult micrometastases may also
be related to the number of metastatic tumor cells present.
The technology of automated quantitative real-time RT-
PCR is now broadly available.14,15 Quantitative RT-PCR,
unlike other approaches to quantification of polymerase
chain reaction (PCR) products, requires no post-PCR prod-
uct manipulation and can rapidly process many samples (96
reactions in 3 to 4 hours). The purposes of this study were
(1) to evaluate the utility of CEA mRNA as a marker for
NSCLC occult micrometastases with standard RT-PCR and
(2) to develop a quantitative RT-PCR assay for CEA mRNA
for quantitation of occult micrometastatic tumor burden.
Methods
Patients and Specimens
Institutional review board approval was obtained for all studies.
Tissue samples were collected from patients undergoing surgery at
institutions participating in Cancer and Leukemia Group B
(CALGB) 9761. Eligible patients had radiographically suspected
or biopsy-proven NSCLC classified as clinical stage I (T1 N0 or
T2 N0) by computed tomographic scan, with the planned treat-
ment of a thoracotomy and resection. Patients with computed
tomographic evidence of N2 disease (lymph nodes ≥1.0 cm) with
negative results of mediastinoscopy were also eligible. All patients
enrolled in the study have not had previous chemotherapy or
mediastinal radiotherapy. Patients also had no history of previous
lung cancer or concomitant malignancy.
At operation, immediately after thoracotomy incision, medi-
astinal lymph nodes from all accessible lymph nodes were har-
vested (stations 4, 7, 8, 9, and 10 on the right and 5, 6, 7, and 10
on the left). Then the appropriate pulmonary resection was per-
formed, and intrapulmonary (station 11) lymph nodes were har-
vested. All lymph node specimens were divided in two: half of
each node was sent for routine pathologic testing and the other half
was immediately snap-frozen in liquid nitrogen for these studies.
At each institution a surgical pathologist staged the primary
tumor in the submitted lung specimen and then provided the par-
ticipating surgeon with a primary tumor sample that was also
snap-frozen. Tissue samples from participating CALGB institu-
tions were shipped on dry ice to our laboratories at the University
of Minnesota. 
Because eligibility to enter the study was open to patients with
suspected or documented NSCLC, tissue specimens were obtained
from patients without cancer and from patients with N1 and N2
disease. These tissue samples were not used in the primary analy-
Conclusions: Standard and quantitative real-time reverse–transcriptase polymerase
chain reaction for carcinoembryonic antigen detected occult metastases in patients
with stage I non–small cell lung cancer at similar rates; both upstaged about 50%
of cases. Quantitative reverse–transcriptase polymerase chain reaction allows esti-
mation of the number of metastatic cells per lymph node, however, which poten-
tially allows greater precision in predicting recurrence risk.
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sis for this study; however, they were used as an internal source of
negative (patients without cancer) and positive (patients with N1
and N2 disease) control specimens for RT-PCR assays.
Tissue Storage
Until molecular analysis was performed, frozen tissue specimens
from primary tumors, lymph nodes, RNA, and complementary
DNA (cDNA) were stored at –86°C.
Cell Lines and Cell Culture
The HTB-174 (human lung adenocarcinoma) and NIH/3T3
(murine fibroblast) cell lines were purchased from American Type
Culture Collection (Rockville, Md) and cultured as recommended
in medium supplemented with 10% fetal bovine serum (BioSource
International, Inc, Camarillo, Calif).
Cell Line Dilutions for CEA mRNA Standard Curves
For these experiments the CEA-expressing cell line HTB-174 and
the CEA-negative cell line NIH/3T3 were cultured to near 80%
confluence, washed with sterile phosphate-buffered saline solu-
tion, trypsinized, centrifuged and washed, and quantitated with a
hemocytometer. CEA-expressing cells (10-fold serial dilutions)
were mixed with 107 NIH/3T3 cells (background cells), and total
cellular RNA was extracted.
Nucleic Acid Extraction
Total cellular RNA was extracted from designated tissues with the
Trizol method (Life Technologies, Inc, Rockville, Md) as we have
previously described elsewhere.5 Frozen tissue (100 mg) was washed
twice with phosphate-buffered saline solution and lysed in 1 mL
Trizol. Extraction of total RNA yielded 100 µg of whole-cell RNA
from 1 mg of tissue. All RNA samples were treated with deoxyri-
bonuclease before RT-PCR processing to eliminate any potential
genomic DNA. RNA was quantitated by spectrophotometry.
Preparation of cDNA
Total cellular RNA was reverse transcribed with the Gene-Amp
system (PE Corporation, Norwalk, Conn) with random hexamer
priming, as previously described.5 Briefly, random hexamers (2.5
mmol/L) were annealed to 5 µg of total RNA for 10 minutes at
25°C. Reverse transcription (Multiscribe Reverse Transcriptase;
PE Corporation) was performed for 30 minutes at 48°C, followed
by enzyme inactivation at 95°C for 5 minutes.
Standard CEA RT-PCR
Standard CEA RT-PCR was performed with a nested PCR
approach, as previously described.10 In brief, CEA primers that
spanned a 160–base pair (bp) fragment of the CEA open reading
frame were synthesized and purified commercially (Genosys
Biotechnology, Woodland, Tex). Primer sequences used were as
follows: A, 5´-TCTGGAACTTCTCCTGGTCTCTCAGCTGG-3´;
B, 5´-TGTTAGCTGTTGCAAATGCTTTAAGGAAGAAGC-3´;
and C, 5´-GGGCCACTGTCGGCATCATGATTGG-3´. In a 25-µL
final volume of 20-mmol/L tris(hydroxymethyl)aminomethane, pH
8.4, 50-mmol/L potassium chloride, 1.5-mmol/L magnesium chlo-
ride, 200-µmol/L deoxyadenosine triphosphate, 200-µmol/L
deoxycytidine triphosphate, 200-µmol/L deoxyguanosine triphos-
phate, 200-µmol/L deoxythymidine triphosphate, and 0.05 units
Taq DNA polymerase (Life Technologies), 200 ng cDNA was
amplified for 20 cycles of PCR at 95°C (1 minute) and 72°C (2
minutes) with primers A and B (200 nmol/L). A final extension step
was performed at 72°C for 10 minutes. For second-round PCR, 1
µL of the first-round PCR product was subjected to 30 cycles of
PCR at 95°C (1 minute), 69°C (1 minutes), and 72°C (2 minutes).
Final extension was again performed at 72°C for 10 minutes. For
analysis of PCR products, 10 µL of PCR product was analyzed by
2% agarose gel electrophoresis, with ethidium bromide staining
used for PCR product analysis. In initial experiments the 131-bp
PCR product was eluted and its identity was confirmed by
sequence analysis.
CEA quantitative RT-PCR
For quantitative RT-PCR, a TaqMan probe and primer set for CEA
was constructed with the PE Biosystems primer design software
(PE Biosystems, Foster City, Calif). The TaqMan probe and
primer set for β-actin was obtained commercially (PE
Biosystems). Primer sequences spanned intron-exon junctions to
avoid contaminating quantitative RT-PCR product with genomic
DNA. To confirm the total gene specificity of sequences derived
for primers and probes, we performed BLASTn (National Center
for Biotechnology Information, Bethesda, Md) searches against
dbEST and the nonredundant set of GenBank, European
Molecular Biology Laboratory, and DNA Data Bank of Japan
database sequences.
In a 50-µL PCR reaction (final volume after cDNA added),
components included 1× TaqMan buffer, 200-mmol/L deoxyadeno-
sine triphosphate, 200-mmol/L deoxycytidine triphosphate,
200-mmol/L deoxyguanosine triphosphate, 200-mmol/L deoxy-
thymidine triphosphate, 200-mmol/L deoxyuracil triphosphate,
5-mmol/L magnesium chloride, 1.25 units AmpliTaq Gold (PE
Biosystems), 0.5 units AmpErase uracil N-glycosylase (PE
Biosystems), 200-nmol/L 5´ primer (5´-GAGGCTCCTGCT-
CACAGCC-3´), 200-nmol/L 3´ primer (5´-TCAATAGT-
GAGCTTGGCAGTGG-3´), and 100-nmol/L TaqMan probe
(5´-CACTTCTAACCTTCTGGAACCCGCCC-3´). Then 200 ng
of cDNA was added and subjected to the following cycling condi-
tions in the PE Biosystems Prism 7700: 50°C for 2 minutes, 95°C
for 10 minutes, and 45 cycles at 95°C for 30 seconds, at 68°C for
30 seconds, and at 72°C for 60 seconds. Each assay included a stan-
dard curve (described previously) and no-template control.
Samples were processed in triplicate. Products were confirmed by
2% agarose gel electrophoresis with ethidium bromide staining. In
initial experiments the expected 69-bp product was also eluted
from the agarose gel, with identity confirmed by sequence analysis.
For data analysis, fluorescence emission from the reporter dye
(FAM-6-carboxyfluorescein), a covalent modification to the 5´
end of the TaqMan probe, exhibited peak fluorescence emission at
518 nm. A charge-coupled-device camera on the PE Biosystems
Prism 7700 instrument collected the laser-excited emission from
each sample for real-time analysis of data. With the threshold
cycle (CT) defined as the fractional cycle number at which the flu-
orescence increases with respect to background, the relative
amounts of mRNA were calculated. Where appropriate, results are
reported as mean ± SD. For our analysis a lymph node station was
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considered positive for CEA and β-actin if it had >1000
micrometastatic cells (sensitivity of the assay). For both genes this
typically corresponded to a CT of less than 42. Coefficient of vari-
ation for triplicate reactions was less than 10%. Coefficient of
variation between assays was also less than 10%.
Results
Patients
Characteristics of patients included in our analysis are
summarized in Table 1. Patients had 32 adenocarcinomas,
16 squamous cell carcinomas, and 5 undifferentiated
tumors. In all, 53 patients had stage I NSCLC (29 T1 N0
and 24 T2 N0).
Standard CEA RT-PCR
Studies were first conducted to establish the sensitivity of
CEA RT-PCR by analysis of a known number of CEA-
positive tumor cells in a background of CEA-negative cells.
The RT-PCR assay had a sensitivity of 104 HTB-174 lung
carcinoma cells in 107 background NIH/3T3 cells (Figure
1). Identical results were also obtained with K562 cells (a
CEA-negative human leukemia cell line) as background
cells (data not shown). Then we analyzed lymph nodes for
CEA mRNA with the nested RT-PCR assay. Initially 23
control lymph nodes from 6 patients without malignancy
were tested (3 patients with pulmonary fibrosis, 2 patients
with granulomatous disease, and 1 patient with blastomy-
cosis). CEA mRNA was not detected in any of the control
lymph nodes analyzed. A representative gel from a patient
with pulmonary fibrosis is presented in Figure 2. Next 53
primary tumor and 232 lymph node specimens from 53
patients with stage I NSCLC were tested for CEA mRNA.
Figure 3, A, shows a representative gel from a patient with
T2 N0 disease with 2 of 4 lymph node stations expressing
CEA mRNA according to RT-PCR. β-Actin was routinely
amplified by RT-PCR in all samples in this study; this was
indicative of total RNA integrity (data not shown). For
internal assay validation a hematoxylin and eosin–positive
lymph node station (11L) from a patient with T2 N1 disease
was tested and found positive by RT-PCR (Figure 3, B). Of
the 53 primary tumors analyzed, 39 (73.6%) were CEA pos-
itive. Of the 232 lymph node specimens, 38 (16.4%) were
TABLE 1. Clinical and pathologic characteristics of study
patients
No.
Stage IA 29
IB 24
Histologic type Adenocarcinoma 32
Squamous cell carcinoma 16
Undifferentiated 5
Figure 1. Sensitivity of standard CEA RT-PCR. PCR reactions were analyzed by ethidium bromide–stained 2% agarose
gel electrophoresis. Expected length of amplified PCR product representing CEA mRNA was 131 bp. Lane M, 100-bp
molecular weight marker; lane 1, negative control; lane 2, NIH/3T3 cells. Remaining lanes represent serial dilutions
of HTB-174 lung adenocarcinoma CEA-positive control cells mixed with 107 NIH/3T3 background cells.
TABLE 2. Detection of CEA mRNA by conventional versus
quantitative RT-PCR in patients with stage I NSCLC
Standard Quantitative
CEA RT-PCR CEA RT-PCR
Total patients tested 53 53
Total negative nodes 232 232
according to hematoxylin
and eosin stain
Positive lymph nodes 38 (16.4%) 59 (25.4%)
TABLE 3. RT-PCR restaging of stage I NSCLC disease
Restaged cases
Stage according to hema- Stage according Standard Quantitative
toxylin and eosin staining to RT-PCR RT-PCR RT-PCR
IA IIA 3 5
IA IIIA 8 10
IB IIIB 2 1
IB IIIA 10 14
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CEA positive (Table 2). These 38 CEA mRNA-positive
lymph nodes were distributed among 23 (43.4%) of the 53
patients with stage I NSCLC as follows: 1 positive lymph
node in 13 patients, 2 positive lymph nodes in 7 patients, 3
positive lymph nodes in 1 patient, 4 positive lymph nodes in
1 patient, and 5 positive lymph nodes in 1 patient. The
potential stage changes are shown in Table 3. All patients
with CEA-positive lymph node specimens also had CEA-
positive primary tumor specimens.
Quantitative CEA RT-PCR
After establishment of a reliable assay with a standard PCR
approach, we extended these experiments to estimate with
quantitative RT-PCR the number of CEA-expressing cells
in lymph nodes of patients with NSCLC. For assay devel-
opment CEA expression was initially tested on several
tumor cell lines, and the assay sensitivity was then deter-
mined. According to quantitative RT-PCR, both the HTB-
174 and MCF-7 tumor cell lines (both CEA positive)
expressed CEA mRNA. CEA mRNA was not detectable in
NIH/3T3 cells or K562 cells (both CEA negative). With the
same tumor cell line dilution experiments as in the standard
RT-PCR assay, we found the sensitivity of CEA mRNA
detection to be 103 HTB-174 lung carcinoma cells in 107
background NIH/3T3 cells. Identical results were obtained
with K562 cells as background cells (data not shown). Next,
8 lymph nodes from 2 patients without malignancy (1
patient with pulmonary fibrosis and 1 patient with blasto-
mycosis) were tested by quantitative RT-PCR for CEA
mRNA. No CEA mRNA was detected (CT >45).
We then performed quantitative RT-PCR analysis on pri-
mary tumors and lymph nodes from the same 53 patients
with stage I NSCLC. Of the 53 primary tumors, 48 (90.5%)
were positive for CEA mRNA. Of the 232 lymph node
specimens analyzed, 59 (25.4%) were positive for CEA
mRNA (Table 2). Figure 4 shows a representative amplifi-
cation plot of a patient’s primary tumor and lymph nodes.
These 59 CEA-positive lymph nodes were distributed
among 30 (56.6%) of the 53 patients as follows: 1 positive
lymph node in 13 patients, 2 positive lymph nodes in 10
patients, 3 positive lymph nodes in 4 patients, 4 positive
lymph nodes in 2 patients, and 5 positive lymph nodes in 1
patient. The potential stage changes are shown in Table 3.
All patients with CEA-positive lymph node specimens also
had CEA-positive primary tumor specimens.
For quantitative analysis of the number of metastatic
tumor cells per lymph node, standard curves were created
from serially diluted CEA-expressing tumor cell lines in a
background of murine fibroblasts. Regression analysis of
these standard curves was used to examine the linear rela-
tionship between starting quantity and CT. This analysis
routinely yielded excellent correlation (r = 0.99). When CT
values of lymph nodes were compared with tumor cell line
standard curves, estimated occult micrometastatic burden
ranged from 1.0 × 103 to 3.2 × 105 micrometastatic cells per
lymph node station. The median cell number was 7190
tumor cells per lymph node station.
Analysis of variance was used to examine the relation-
ship between the estimated micrometastatic tumor cell bur-
den determined by quantitative RT-PCR with primary tumor
histologic type and T status. No statistical difference was
observed between adenocarcinomas (median 7425 tumor
cells), squamous cell carcinomas (median 11,165 tumor
cells), and undifferentiated tumors (median 7190 tumor cells).
Figure 2. Standard RT-PCR for CEA mRNA in lymph node stations
of patients without evidence of malignancy. RT-PCR reactions
were analyzed by ethidium bromide-stained 2% agarose gel elec-
trophoresis. Expected length of amplified PCR product represent-
ing CEA mRNA was 131 bp. Lane M, 100-bp molecular weight
marker; lane 1, negative control; lane 2, HTB-174 lung adenocar-
cinoma positive control; lane 3, lung mass (pulmonary fibrosis);
lane 4, lymph node station 4R; lane 5, lymph node station 7; lane 6,
lymph node station 10; lane 7, lymph node station 11.
Figure 3. Standard RT-PCR for CEA mRNA in lymph node stations of
patients with NSCLC. PCR reactions were analyzed by ethidium bro-
mide-stained 2% agarose gel electrophoresis. Expected length of
amplified PCR product representing CEA mRNA was 131 bp. Lane M,
100-bp molecular weight marker; lane 1 (Mock), negative control;
lane 2, HTB-174 lung adenocarcinoma positive control; other lanes,
primary tumor and mediastinal lymph node stations as labeled. A,
Patient with T2 N0 disease; B, patient with T2 N1 disease.
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Of the 134 T1 N0 lymph node stations analyzed, 32
(23.9%) were positive for CEA mRNA. This was not sig-
nificantly different from the 26 (27.6%) of 98 CEA-positive
T2 N0 lymph node stations. Further, no difference was
observed between T1 (median 7730 tumor cells) and T2
(median 6580 tumor cells) tumors.
Discussion
This represents the first report demonstrating the utility of
CEA as a marker for micrometastatic disease in lymph
nodes of patients with NSCLC. CEA is a member of a het-
erogeneous group of oncofetal membrane glycoprotein
antigens that are frequently overexpressed in epithelial-
derived tumors. Because of this overexpression, CEA
mRNA detection in the lymph nodes, serum, and bone mar-
row of patients may be of value as a marker for the presence
of occult micrometastases. Recently CEA mRNA detection
by RT-PCR was shown to predict a significantly worse
prognosis in patients with stage II colon cancer, supporting
its potential value as a marker for occult micrometastases.16
Few studies have evaluated CEA mRNA expression by
RT-PCR in NSCLC.11,12,17,18 Castaldo and coworkers11
evaluated RT-PCR for CEA mRNA detection in 24 patients
with advanced NSCLC. CEA mRNA was detected in the
peripheral blood of 8 of 10 patients with distant metastases.
Of 14 patients without distant metastases, 4 had CEA-posi-
tive samples; 2 of those 4 had distant metastases develop
within 6 months. Kurusu and colleagues12 tested peripheral
blood samples of NSCLC patients before operation and
then 2 to 3 weeks after tumor resection. Of the 103 patients
in their analysis, 62 had CEA mRNA detected before the
operation; of these, 27 still had CEA mRNA detected after
the operation, which suggests persistent systemic disease.
Neither study provided data on tumor recurrence.
The technique of quantitative RT-PCR uses a sequence-
specific oligonucleotide probe with a covalently attached
fluorescent reporter and quencher dye. When the probe is
intact, the quenching dye absorbs the fluorescent energy of
the reporter dye. If the target molecule of interest (in this
case CEA mRNA) is present, the specific oligonucleotide
probe will anneal to it. During the PCR extension phase, the
probe is cleaved by the 5´ to 3´ exonuclease activity of Taq
DNA polymerase, thus increasing the reporter dye’s emis-
sion. Curves plotting relative fluorescence change against
PCR cycle number are constructed, and the point of fluo-
rescence increase above background is calculated. From
Figure 4. Representative quantitative RT-PCR amplification plot of patient with stage I NSCLC. Change in normalized
reporter signal (∆Rn, y-axis) plotted versus cycle number (x-axis). Amplification curves for primary tumor and lymph
node stations are shown. Amplification curves are as follows: orange, primary tumor; green, station 4R; blue, station
9; red, station 10; dark blue; station 11; yellow, station 7.
490 The Journal of Thoracic and Cardiovascular Surgery • March 2002
General Thoracic Surgery D’Cunha et al
ED
ITO
RIA
L
CH
D
G
TS
G
TS
ET
CSP
TX
this calculation the CT is determined. Because the CT value
decreases linearly with increasing target molecule quantity
in the input sample, it provides quantitative measurement.
Other reports have attempted to quantitate occult
micrometastatic burden by analyzing lymph nodes from
patients with colorectal and gastric cancers to detect CEA
mRNA with a variant of real-time RT-PCR that employs
nonspecific DNA-binding fluorescent dyes.19,20 A potential
disadvantage of this approach is its inherent lack of speci-
ficity. Because of this, PCR-product discrimination is nec-
essary through the additional step of double-stranded
DNA-based fluorescence melting curve analysis. The tech-
nique in our study used a CEA sequence-specific probe for
quantitative RT-PCR.
For normalization of CEA mRNA values in each speci-
men, we also quantitated β-actin mRNA levels in RT-PCR
(standard and quantitative RT-PCR) experiments. β-Actin
levels varied among samples but did not differ significantly
overall. Because our results were not significantly altered by
CEA to β-actin normalization, the rationale for reporting nor-
malized data in this setting may be limited.20 Also, the total
number of cancer cells in a given lymph node station, rather
than the cancer to noncancer cell ratio, may be the critical
parameter predicting recurrence. For these reasons we have
reported unnormalized CEA mRNA data as an indicator of
occult micrometastatic burden. This has been internally vali-
dated through an analysis of patients with stage II and stage
III disease, who uniformly had higher numbers of metastatic
cells in their hematoxylin and eosin–positive lymph nodes.
The results of our quantitative RT-PCR assay suggest
that the number of metastatic tumor cells in a lymph node
can be estimated by measurement of CEA mRNA abun-
dance. How the quantity of CEA mRNA correlates with the
number of tumor cells is imprecisely defined. Others have
previously shown CEA mRNA and protein expressions to
be linearly coupled.21 Thus if the same cell line is used con-
sistently, a standard curve derived from CEA mRNA levels
should allow reproducible estimates of tumor cell number.
In our analysis quantitative RT-PCR appeared to be more
sensitive than standard PCR for detecting CEA mRNA.
Quantitative RT-PCR found 20 additional CEA-positive
lymph nodes (all negative by standard PCR), potentially
upstaging 7 additional cases. This finding is consistent with
the 10-fold increased sensitivity of the quantitative RT-PCR
technique relative to standard RT-PCR in our cell line exper-
iments. The finding of 20 additional CEA-positive lymph
node stations by quantitative RT-PCR is entirely related to the
increased sensitivity of the assay, because the number of esti-
mated micrometastatic cells in quantitative RT-PCR–positive
and standard RT-PCR–negative lymph node stations was less
than 10,000 tumor cells per lymph node station. Quantitative
RT-PCR may therefore offer greater sensitivity than standard
RT-PCR for detecting occult micrometastases.
Although quantitative RT-PCR does appear to have
greater sensitivity than standard RT-PCR for detection of
occult micrometastases, the results are remarkably similar
and consistent. Standard RT-PCR and quantitative RT-PCR
demonstrate similar rates of lymph node occult
micrometastatic detection (16.4% and 25%, respectively)
and potential upstaging (43.4% and 56.6%, respectively).
Quantitative RT-PCR trended toward discriminating more
patients with micrometastatic disease, and any significant
differences in sensitivity between the two techniques will
probably be identified by the completion of CALGB 9761.
In additional to the advantage of quantitative analysis,
quantitative RT-PCR also decreases the amount of experi-
mental time (from 8 hours with standard RT-PCR to 3 hours
with quantitative RT-PCR) and affords a 2-fold increase in
samples analyzed per experiment.
The similarity in numbers of tumor cells per lymph node
station determined by quantitative RT-PCR in patients with
T1 N0 versus T2 N0 disease is surprising in light of the
known survival difference between these groups of patients.
Further, the rates of CEA-positive lymph nodes were simi-
lar in patients with T1 N0 and T2 N0 disease (23.9% and
27.6%, respectively). It remains unclear whether survival
differences between patients with T1 and T2 lesions is
accounted for solely by the presence of undetected metasta-
tic nodal disease. For example, a variety of molecular
abnormalities have been associated with increased tumor
size that may account for differences in patient outcome
independent of micrometastatic disease.22,23
In summary, quantitative RT-PCR can estimate the num-
ber of micrometastatic cells per lymph node, potentially
allowing greater precision than either standard RT-PCR or
immunohistochemical analysis in assessing tumor recur-
rence risk. The potential stage change rates are similar to
the known 5-year survival rates for surgically resected stage
I disease. The comparative prognostic values of immuno-
histochemical analysis, standard RT-PCR, and quantitative
RT-PCR should be clarified by the tumor recurrence rates
and survival data provided by the results of CALGB 9761.
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Discussion
Dr James Luketich (Pittsburgh, Pa). This exciting work is
timely in light of the interest in neoadjuvant therapy for early-
stage lung cancer. We have done some similar work with
esophageal cancer.
I have two questions. First, did background gene expression of
CEA seem to be present in your patients that did not have lung
cancer (benign negative control)? We have seen that as a possible
complicating problem for the specificity of this assay in determin-
ing what really represents background gene expression versus
what represents a micrometastasis. Second, did you find any cor-
relation with a worsening prognosis in terms of clinical outcomes
and cancer recurrences?
Dr D’Cunha. To address the first question, in our 6 patients
with benign conditions we did not see any background expression
under the described assay conditions, although it was a relatively
small number of patients. Perhaps when we expand our negative
control population, which we will do as part of our ongoing work,
we will see some background expression. I think that the advan-
tage of quantitative RT-PCR is that it potentially allows you to at
least exclude the population that would express it at baseline.
To address the second question, this is part of a prospective,
multi-institutional clinical trial, and we have not looked at the sur-
vival data and compared our results with that yet. We will be doing
that as we get more patients, and then we should be able to corre-
late those results.
Dr Raphael Bueno (Boston, Mass). I think that molecular
markers are going to help us significantly in classification and
staging. I do have a cautionary note. Until you can show that the
CEA correlates with the actual presence of cancer cells, it is incor-
rect to use the term micrometastatic disease, which at least in my
mind implies that there are cancer cells there. The CEA levels
could be representing background noise, or the antigen could be
made by cells in the process of carcinogenesis. I suggest that we
add molecular markers to our current staging scheme, as we do in
breast cancer with progesterone and estrogen receptors, to direct
therapy rather than just upstaging the cancer as you suggest.
Dr David Harpole, Jr (Durham, NC). For the audience, these
data are part of a large multi-institutional Cancer and Leukemia
Group B Thoracic Surgery Subcommittee study, which is analyz-
ing these data in more than 500 patients. We anxiously await the
complete results from Dr Maddaus’ laboratory.
I have two questions. First, the abstract and presentation omitted
the percentage of the primary tumors that expressed CEA. It would
have to be present in most to accurately reflect micrometastatic dis-
ease in lymph nodes. Was this the case? Second, have you attempted
these techniques on formalin-fixed, paraffin-bedded tumors? I know
that it is difficult, but it can be done. We have done it in our labora-
tory, and it clearly makes these techniques much more applicable at
most North American hospitals.
Dr D’Cunha. With respect to the paraffin-embedded tissue, we
have not tried that, but I know that it is being done and potentially
would be an area for our future investigation. With respect to the
percentage of positive results in the primary tumors, that is an
excellent question. In the standard RT-PCR the primary tumors
were 75% positive for CEA, whereas in quantitative RT-PCR the
rate was about 90%. We attribute that difference to the 10-fold
increased sensitivity that the quantitative RT-PCR assay affords.
